A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

A 40-year-old woman developed a rare and potentially life-threatening “flesh-eating” infection of the genital and perineal region about a week after shaving her bikini line and an application of herbal preparation.

The woman, a mother of four with a BMI of 39 kg/m², was diagnosed with Fournier gangrene, a severe form of necrotizing fasciitis that can rapidly destroy soft tissue around the genitals and perineum.

She spent 77 days in hospital undergoing treatment, wound care and reconstruction. Complete wound healing was documented by Day 121, reported doctors from King Saud University in Riyadh, Saudi Arabia, in the American Journal of Case Reports.

Severe Pain and Swelling

The woman presented with worsening pain and swelling of the left labia that had spread toward the area above the pubic bone. She also experienced vomiting and lower abdominal pain.

About a week before admission, she had undergone perineal shaving and had a herbal preparation applied to her vulva by an alternative practitioner. She had not used antibiotics or other topical treatments before seeking medical care.

On admission, her heart rate was elevated at 140 beats per minute, although she had no fever and her blood pressure remained normal. Examination showed marked tenderness and swelling, while laboratory tests indicated a significant inflammatory response.

Samples taken from the infected wound grew several different types of bacteria (E. coli, Klebsiella pneumoniae, and Enterobacter cloacae). However, no bacteria were detected in her bloodstream.

Multiple Surgeries

After doctors diagnosed her with Fournier gangrene, they performed urgent surgical debridement to remove the affected tissue.

She subsequently underwent multiple surgical re-explorations and negative-pressure wound therapy.

She was initially given broad-spectrum antibiotics, and later amoxicillin-clavulanate.

What Is Fournier Gangrene?

Fournier gangrene is a rare, rapidly progressive form of necrotizing fasciitis affecting the perineum and external genitalia. It is often described as a “flesh-eating” infection because bacteria can cause rapid destruction of skin and underlying soft tissue.

The condition is much more common in men, but women can also develop it. Reported male-to-female ratios range from 10:1 to 40:1.

Risk factors include diabetes, obesity, immunosuppression, malnutrition, peripheral vascular disease, kidney disease, malignancy and other serious underlying conditions. However, Fournier gangrene can also occur in people without the classic risk factors.

Local trauma, disruption of the skin barrier and invasive or cosmetic procedures can potentially provide an entry point for infection.

Why Fournier Gangrene Can Be Missed in Women

The researchers noted that Fournier gangrene may be underrecognized in women, partly because its symptoms can initially resemble a gynecological condition.

Early symptoms may include severe pain, swelling, redness and tenderness around the genital or perineal area. As the infection progresses, tissue destruction, skin discoloration, blisters or systemic signs of severe infection may develop.

"While men are more frequently affected, women should not be assumed to be at low risk. Severe or rapidly worsening pain and swelling around the genital or perineal region, particularly when accompanied by systemic symptoms, warrants urgent medical evaluation," the team said.

Treatment generally requires emergency surgical removal of dead and infected tissue along with broad-spectrum antibiotics and intensive supportive care. Survivors may require multiple operations, prolonged hospitalisation and complex wound management.

How Serious Is Fournier Gangrene?

Fournier gangrene is a medical emergency. Although rare, it can progress rapidly and become fatal if treatment is delayed.

The condition has historically been associated with high mortality, with risk increasing when diagnosis and surgical treatment are delayed.

A 62-year-old man in Australia died after his urgent heart surgery was cancelled twice. A state coroner later found that failures in an overworked health system contributed to his death.

Petar Josipovic had been diagnosed with moderate-to-severe aortic regurgitation and coronary artery disease. He was placed on the cardiothoracic surgery waiting list at Royal Adelaide Hospital as a Category 1 patient, meaning his surgery was expected to take place within 30 days.

However, his operation, initially scheduled for August 14, 2023, was cancelled twice to make room for higher-priority emergency patients. It was eventually rescheduled for August 25.

The day before his surgery, Josipovic was rushed to the emergency department after his condition deteriorated and suffered a cardiac arrest.

Doctors performed an emergency aortic valve replacement and coronary artery bypass surgery, but he developed severe complications and died about three weeks later in the ICU.

Coroner Says His Death Was Linked To Failures In Healthcare System

South Australian State Coroner David Whittle found that Josipovic's death was potentially preventable and called for a sweeping independent review of how cardiac surgery patients are assessed, listed and managed while waiting for operations.

The coroner, however, did not attribute the repeated cancellations to individual negligence. “I do not make any finding that the decisions that led to the cancellations were the result of ill-will or lack of due care,” Whittle said.

Instead, he said a health system under immense pressure was bound to have systemic failures. He also said that staff were unable to recognise the extent of the patient's deterioration before it was too late.

Also read: Stopping Statins After 75 May Not Raise Death Risk In Low-Risk Adults: The Lancet Study

Why Was An Urgent Cardio Surgery Repeatedly Delayed?

The inquest heard that reduced intensive care capacity had put additional pressure on the cardiothoracic service. ICU capacity reportedly fell from 24 beds to 16 following the move to the new hospital site, meaning urgent procedures could be postponed when beds were unavailable.

Josipovic's case also highlighted the problem of keeping track of patients whose condition worsens while they remain on surgical waiting lists.

The coroner noted that Josipovic had been advised to attend the emergency department on occasions but did not do so. This meant clinicians did not have the opportunity to physically reassess his condition and fully appreciate how much his risk had increased.

Also read: More Indians Face Twin Burden of Hypertension and Diabetes After 40: Why Preventive Healthcare Is Important

Coroner Recommended Urgent Changes

Whittle recommended an independent external review of cardiothoracic surgical listing practices, covering the patient's entire medical history from referral and assessment to waiting-list management and hospital resources.

He also called for standard guidelines across South Australia's health networks so staff know exactly what advice to provide when patients waiting for surgery report that their condition is worsening.

The case has renewed concerns about what happens when hospitals have to balance urgent operations against limited beds and resources.

The case has also highlighted an important issue. For patients waiting for time-sensitive procedures, a delay is not always simply a longer wait. In some cases, the patient's clinical condition can change while they remain on the list

US President Donald Trump recent move of overhauling childhood vaccine recommendations has sparked debates across the globe. Several US states have opposed to it too, refusing to follow Washington’s lead.

Trump signed the executive order on August 10, calling for federal childhood vaccine recommendations to be narrowed to vaccines routinely recommended for children against 11 diseases, down from 18 at the end of 2024.

It also calls for the measles, mumps and rubella (MMR) vaccine to be given as three separate shots and says childhood vaccines should, where feasible, be administered during separate medical visits.

The order also asks states to review their school vaccination requirements. But there is an important question here: states, not the federal government, generally set vaccine requirements for children attending schools.

Which States Are Refusing To Follow Trump’s Directives?

At least 29 states and Washington, DC, had already rejected at least some federal vaccine guidance, choosing instead to rely on recommendations from medical organisations such as the American Academy of Pediatrics (AAP).

Among the states that have opposed Trump's order and maintained independent, medicine-based vaccine policies are Colorado, Maine and Washington.

Colorado has gone further by passing legislation allowing the state to rely on organisations including the AAP, American Academy of Family Physicians and American College of Obstetricians and Gynecologists when setting its childhood vaccine policy, rather than depending on federal CDC directive.

Maine has also said it will continue following guidance from established medical and public-health organisations instead of Trump's order.

Washington state officials said its school vaccine requirements have not changed for the upcoming academic year and remain based on recommendations from trusted medical and public-health experts.

This means Trump's order does not automatically change every child's vaccination schedule across the United States. The legal and political battle is likely to continue state by state.

Also read: What Trump’s Childhood Vaccine Order Means: When Will It Take Effect?

Trump's MRI Proposal Sparked Controversy

The MMR vaccine has been used as a combined vaccine for several decades. Trump’s order calls for separate measles, mumps and rubella vaccines, once they become available in the US.

Public-health experts have warned that separating vaccines could mean more appointments, higher costs and more chances for children to contract these infections as they may remain unvaccinated between doses.

The World Health Organization has also defended established immunisation schedules, saying they are based on decades of scientific evidence and proven clinical trials

The timing is particularly controversial as the US has already recorded 2,465 confirmed measles cases in 2026 as of August 6, according to the CDC.

Also read: Kennedy Announces Food Policy Reforms Under Trump’s MAHA Agenda: What Has Been Proposed?

Countries React To Trump's Vaccine Recommendation

The UK has taken a stand against Trump's newly proposed vaccine recommendation. On August 12, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed that childhood vaccines are safe and effective and said there is no evidence that vaccines cause autism.

“The benefits of vaccination are endorsed by the NHS and all major UK public health and paediatric bodies,” said Dr Alison Cave, chief safety officer at the MHRA. She urged parents to follow NHS vaccination has an guidance.

The UK's routine schedule continues to use combination vaccines, including the six-in-one vaccine, and since January 2026 has included a universal two-dose chickenpox programme through the combined MMRV vaccine.